Article: Evolving into an international biotech market driver
In 20 years BIOCAD grew from a pharma startup outside of Moscow to an international company producing both biosimilars and original products.
List view / Grid view
In 20 years BIOCAD grew from a pharma startup outside of Moscow to an international company producing both biosimilars and original products.
13 January 2022 | By
BIOCAD is a full-cycle drug development company, from molecule search to mass production and marketing support.
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market